These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26722831)

  • 1. [Anti-rotavirus and intussusception: no evidence to discontinue the universal vaccination policy].
    Bonanni P; Signorelli C
    Ig Sanita Pubbl; 2015; 71(5):549-57. PubMed ID: 26722831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Post-Licensure Data on Benefits and Risks of Vaccination to Inform Vaccine Policy: The Example of Rotavirus Vaccines.
    Parashar UD; Cortese MM; Payne DC; Lopman B; Yen C; Tate JE
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S377-82. PubMed ID: 26590437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.
    Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM
    Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.
    Shim E; Galvani AP
    Vaccine; 2009 Jun; 27(30):4025-30. PubMed ID: 19389452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotavirus vaccination in Europe: drivers and barriers.
    Parez N; Giaquinto C; Du Roure C; Martinon-Torres F; Spoulou V; Van Damme P; Vesikari T
    Lancet Infect Dis; 2014 May; 14(5):416-25. PubMed ID: 24758998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotavirus vaccination in central Europe.
    Mészner Z; Anca I; André F; Chlibek R; Čižman M; Grzesiowski P; Mangarov A; Pokorn M; Prymula R; Richter D; Salman N; Šimurka P; Tamm E; Tešović G; Urbancikova I; Usonis V; Zavadska D;
    J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):586-96. PubMed ID: 23708638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost of vaccination and cost of sick leave are determinants of cost-effectiveness vaccination against rotavirus].
    Gyrd-Hansen D; Olsen KR
    Ugeskr Laeger; 2012 Feb; 174(8):480-3. PubMed ID: 22348668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain.
    Imaz I; Rubio B; Cornejo AM; González-Enríquez J
    Prev Med; 2014 Apr; 61():116-21. PubMed ID: 24360847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precise reply and clarifications on behalf of Sicilian Public Health Authorities to the case report published by La Rosa and collegues.
    Vitale F; Costantino C; Restivo V; Casuccio N; Corsello G; Palermo M; Tozzo I
    Hum Vaccin Immunother; 2016 Nov; 12(11):2969-2971. PubMed ID: 27560654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014.
    Vesikari T; Van Damme P; Giaquinto C; Dagan R; Guarino A; Szajewska H; Usonis V
    Pediatr Infect Dis J; 2015 Jun; 34(6):635-43. PubMed ID: 25860532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotavirus vaccination: a concise review.
    Vesikari T
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():57-63. PubMed ID: 22882248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the 'European Expert Meeting on Rotavirus Vaccination', Tampere, Finland, 19-20 May 2009.
    Vesikari T; Sutherland D; Jackson AE
    Vaccine; 2009 Dec; 27(52):7222-7. PubMed ID: 19822233
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the potential risks and benefits of infant rotavirus vaccination in England.
    Clark A; Jit M; Andrews N; Atchison C; Edmunds WJ; Sanderson C
    Vaccine; 2014 Jun; 32(29):3604-10. PubMed ID: 24814524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research priorities regarding rotavirus vaccine and intussusception: a meeting summary.
    Tate JE; Steele AD; Bines JE; Zuber PL; Parashar UD
    Vaccine; 2012 Apr; 30 Suppl 1():A179-84. PubMed ID: 22520129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotavirus vaccines, intussusception, and risk-benefit assessments.
    Schwartz JL
    JAMA Pediatr; 2013 Dec; 167(12):1093-4. PubMed ID: 24100526
    [No Abstract]   [Full Text] [Related]  

  • 19. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.
    Patel MM; Clark AD; Glass RI; Greenberg H; Tate J; Santosham M; Sanderson CF; Steele D; Cortese M; Parashar UD
    Vaccine; 2009 May; 27(22):2916-22. PubMed ID: 19428901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic analysis of rotavirus vaccination in Italy.
    Giammanco MD; Coniglio MA; Pignato S; Giammanco G
    Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.